Compare Stocks: PDSB, KZIA, CRBU, and ADCT

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.06 -0.5%	$1.15	$0.78 ▼ $4.98	$134.05M	1.84	1.61 million shs	1.58 million shs
CRBU Caribou Biosciences	$1.30 -0.8%	$1.57	$1.25 ▼ $3.54	$139.37M	2.28	1.17 million shs	1.84 million shs
KZIA Novogen	$10.39 -4.3%	$12.86	$4.86 ▼ $17.40	$134.75M	2.14	366,685 shs	169,907 shs
PDSB PDS Biotechnology	$0.81 -4.4%	$0.49	$0.20 ▼ $1.55	$45.08M	1.46	62.16 million shs	18.84 million shs

The Best Nuclear Energy Stocks to Buy

Nuclear energy is entering a new growth cycle as rising power demand, expanding data centers, and renewed policy support bring the sector back into focus. After strong gains in recent years, the most impactful phase of nuclear investment may still be ahead. This report highlights seven nuclear energy stocks positioned across the value chain—combining near-term revenue with long-term upside as next-generation technologies scale. Click the link below to unlock the full list.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-0.94%	+9.87%	-2.76%	-67.64%
CRBU Caribou Biosciences	0.00%	+2.36%	-19.25%	-20.49%	-24.42%
KZIA Novogen	0.00%	-7.15%	-23.99%	-25.04%	+30.86%
PDSB PDS Biotechnology	0.00%	+173.14%	+285.59%	-15.65%	-29.96%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ADCT ADC Therapeutics	$1.06 -0.5%	$1.15	$0.78 ▼ $4.98	$134.05M	1.84	1.61 million shs	1.58 million shs
CRBU Caribou Biosciences	$1.30 -0.8%	$1.57	$1.25 ▼ $3.54	$139.37M	2.28	1.17 million shs	1.84 million shs
KZIA Novogen	$10.39 -4.3%	$12.86	$4.86 ▼ $17.40	$134.75M	2.14	366,685 shs	169,907 shs
PDSB PDS Biotechnology	$0.81 -4.4%	$0.49	$0.20 ▼ $1.55	$45.08M	1.46	62.16 million shs	18.84 million shs

The Best Nuclear Energy Stocks to Buy

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ADCT ADC Therapeutics	0.00%	-0.94%	+9.87%	-2.76%	-67.64%
CRBU Caribou Biosciences	0.00%	+2.36%	-19.25%	-20.49%	-24.42%
KZIA Novogen	0.00%	-7.15%	-23.99%	-25.04%	+30.86%
PDSB PDS Biotechnology	0.00%	+173.14%	+285.59%	-15.65%	-29.96%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ADCT ADC Therapeutics	2.33	Hold	$5.00	373.93% Upside
CRBU Caribou Biosciences	2.80	Moderate Buy	$7.75	496.15% Upside
KZIA Novogen	2.71	Moderate Buy	$27.33	163.07% Upside
PDSB PDS Biotechnology	2.33	Hold	$9.00	1,017.32% Upside

Current Analyst Ratings Breakdown

Latest PDSB, KZIA, CRBU, and ADCT Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
9/11/2026	PDSB PDS Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Downgrade	Sell (D-) ➝ Sell (E+)
9/10/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy	$40.00
9/1/2026	KZIA Novogen	BTIG Research Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$34.00 ➝ $40.00
8/26/2026	PDSB PDS Biotechnology	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Buy
8/17/2026	ADCT ADC Therapeutics	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$5.00
8/14/2026	PDSB PDS Biotechnology	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Sell (E+) ➝ Sell (D-)
8/14/2026	CRBU Caribou Biosciences	Bank of America Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Buy	$6.00 ➝ $5.00
8/13/2026	KZIA Novogen	Canaccord Genuity Group Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Initiated Coverage	Buy	$29.00
7/17/2026	ADCT ADC Therapeutics	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	CRBU Caribou Biosciences	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)
7/17/2026	KZIA Novogen	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Sell (D-)

(Data available from 9/20/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ADCT ADC Therapeutics	$81.36M	1.66	N/A	N/A	($1.50) per share	-0.70
CRBU Caribou Biosciences	$11.16M	12.49	N/A	N/A	$1.31 per share	0.99
KZIA Novogen	$30K	4,491.94	N/A	N/A	($5.34) per share	-1.95
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	$0.18 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ADCT ADC Therapeutics	-$142.62M	-$0.66	N/A	N/A	N/A	-121.77%	N/A	-32.74%	11/10/2026 (Estimated)
CRBU Caribou Biosciences	-$148.12M	-$1.08	N/A	N/A	N/A	-1,030.42%	-89.11%	-62.47%	11/11/2026 (Estimated)
KZIA Novogen	-$13.41M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	-$34.50M	-$0.64	N/A	N/A	N/A	N/A	-708.18%	-136.50%	11/12/2026 (Estimated)

Latest PDSB, KZIA, CRBU, and ADCT Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/13/2026	Q2 2026	ADCT ADC Therapeutics	-$0.2160	-$0.11	+$0.1060	-$0.11	$18.89 million	$19.25 million
8/13/2026	Q2 2026	CRBU Caribou Biosciences	-$0.3240	-$0.24	+$0.0840	-$0.24	$2.28 million	$1.50 million
8/13/2026	Q2 2026	PDSB PDS Biotechnology	-$0.13	-$0.18	-$0.05	-$0.18	N/A	N/A

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ADCT ADC Therapeutics	N/A	N/A	N/A	N/A	N/A
CRBU Caribou Biosciences	N/A	N/A	N/A	N/A	N/A
KZIA Novogen	N/A	N/A	N/A	N/A	N/A
PDSB PDS Biotechnology	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ADCT ADC Therapeutics	N/A	3.03	2.97
CRBU Caribou Biosciences	N/A	6.49	6.49
KZIA Novogen	N/A	2.87	N/A
PDSB PDS Biotechnology	2.73	0.57	0.57

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ADCT ADC Therapeutics	41.10%
CRBU Caribou Biosciences	77.51%
KZIA Novogen	30.89%
PDSB PDS Biotechnology	26.84%

Insider Ownership

Company	Insider Ownership
ADCT ADC Therapeutics	5.10%
CRBU Caribou Biosciences	8.54%
KZIA Novogen	1.00%
PDSB PDS Biotechnology	8.40%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ADCT ADC Therapeutics	191	127.67 million	121.16 million	Optionable
CRBU Caribou Biosciences	97	107.21 million	98.05 million	Optionable
KZIA Novogen	6	12.97 million	12.84 million	No Data
PDSB PDS Biotechnology	21	55.97 million	51.27 million	Optionable

PDSB, KZIA, CRBU, and ADCT Headlines

Recent News About These Companies

PDS Biotechnology (NASDAQ:PDSB) Upgraded at Wall Street Zen

September 19 at 1:13 AM | americanbankingnews.com

PDS Biotechnology (PDSB) Stock Fair Value Moves Lower After Analyst Cuts And Financing Scrutiny

September 18 at 11:59 PM | finance.yahoo.com

PDS Biotechnology Reports Initial Closing of Private Financing

September 16, 2026 | finance.yahoo.com

Biotech Stocks Gain Ground: PDS Biotech, Clene, Indaptus Lead Movers

September 15, 2026 | rttnews.com

PDS Biotechnology jumps as investors react to PIPE closing and Patrick Soon-Shiong tie-up

September 15, 2026 | quiverquant.comQ

PDS Biotechnology consensus price target decreased by 13.79% to $4.25

September 15, 2026 | msn.com

IBRX Stock Gains As Soon-Shiong’s Nant Capital Backs Second Cancer-Immunotherapy Bet

September 15, 2026 | msn.com

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

September 14, 2026 | finance.yahoo.com

PDS Biotechnology Raises $11.3 Million in Initial Closing of PIPE Led by Nant Capital; Dr. Soon-Shiong Joins Board

September 14, 2026 | quiverquant.comQ

PDS Biotech Announces Initial Closing of up to $22.3 Million PIPE Financing and the Appointment of Dr. Patrick Soon-Shiong to Its Board of Directors

September 14, 2026 | globenewswire.com

FY2026 EPS Estimate for PDS Biotechnology Reduced by Analyst

September 13, 2026 | americanbankingnews.com

Stock Traders Buy Large Volume of PDS Biotechnology Call Options (NASDAQ:PDSB)

September 10, 2026 | americanbankingnews.com

PDS Biotech Raises Up To $22.55M In PIPE Led By Dr. Patrick Soon-Shiong

September 8, 2026 | rttnews.com

PDS Biotechnology Raises $22.6 Million in Equity Funding; Shares Rise

September 8, 2026 | finance.yahoo.com

PDS Biotech Jumps as Soon-Shiong-Backed Financing Eases Funding Pressure

September 8, 2026 | quiverquant.comQ

PDS Biotech soars as it announces up to $22.55 million financing

September 8, 2026 | thepharmaletter.comT

PDS Biotech Announces up to $22.55 Million Financing Led by Dr. Patrick Soon-Shiong, Founder of NantWorks

September 8, 2026 | globenewswire.com

PDS Biotechnology Corporation: PDS Biotech Reports Second Quarter 2026 Financial Results

August 13, 2026 | finanznachrichten.de

PDS Biotech Reports $9.8 Million Second-Quarter 2026 Net Loss

August 13, 2026 | quiverquant.comQ

PDS Biotech Reports Second Quarter 2026 Financial Results

August 13, 2026 | globenewswire.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB, KZIA, CRBU, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

$1.06 -0.01 (-0.47%)

Closing price 09/18/2026 03:59 PM Eastern

Extended Trading

$1.05 0.00 (-0.47%)

As of 09/18/2026 07:55 PM Eastern

ADC Therapeutics SA focuses on advancing its proprietary antibody drug conjugate (ADC) technology platform to transform the treatment paradigm for patients with hematologic malignancies and solid tumors. Its flagship product is ZYNLONTA, a CD19-directed ADC, received accelerated approval from the U.S. Food and Drug Administration and conditional approval from the European Commission for the treatment of relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy. The company is also seeking to continue expanding ZYNLONTA into international markets and into earlier lines of DLBCL and indolent lymphomas, including follicular lymphoma (FL) and marginal zone lymphoma (MZL) as a single agent and in combination through its LOTIS-5 confirmatory Phase 3 clinical trial and LOTIS-7 Phase 1b clinical trial, as well as through investigator-initiated trials (IITs). In addition, it is investigating a CD-22 targeted compound, ADCT-602 that is in a Phase 1/2 investigator-initiated study in relapsed or refractory B-cell acute lymphoblastic leukemia. Further, its clinical-stage pipeline consists of ADCT-601 (mipasetamab uzoptirine) targeting AXL as a single agent and/or in combination in sarcoma, pancreatic, and NSCLC, as well as pre-clinical stage pipeline includes a portfolio of next generation investigational ADCs targeting Claudin-6, NaPi2b, PSMA, and other undisclosed targets. The company was incorporated in 2011 and is headquartered in Epalinges, Switzerland.

Caribou Biosciences NASDAQ:CRBU

$1.30 -0.01 (-0.76%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$1.34 +0.03 (+2.69%)

As of 09/18/2026 07:30 PM Eastern

Caribou Biosciences, Inc., a clinical-stage biopharmaceutical company, engages in the development of genome-edited allogeneic cell therapies for the treatment of hematologic malignancies in the United States and internationally. Its lead product candidate is CB-010, an allogeneic anti-CD19 CAR-T cell therapy that is in phase 1 clinical trial to treat relapsed or refractory B cell non-Hodgkin lymphoma. The company also develops CB-011, an allogeneic anti-BCMA CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory multiple myeloma; and CB-012, an allogeneic anti-CD371 CAR-T cell therapy that is in phase 1 clinical trial for the treatment of relapsed or refractory acute myeloid leukemia. Caribou Biosciences, Inc. was incorporated in 2011 and is headquartered in Berkeley, California.

Novogen NASDAQ:KZIA

$10.39 -0.47 (-4.33%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$10.60 +0.21 (+2.02%)

As of 09/18/2026 07:30 PM Eastern

Kazia Therapeutics Limited operates as an oncology-focused biotechnology company. The company's lead development candidate is Paxalisib, a small molecule, brain-penetrant inhibitor of the PI3K/AKT/mTOR pathway, which is developed as a potential therapy for glioblastoma. It also develops EVT801, a small-molecule selective inhibitor of vascular endothelial growth factor receptor 3. The company was formerly known as Novogen Limited and changed its name to Kazia Therapeutics Limited in November 2017. Kazia Therapeutics Limited was incorporated in 1994 and is based in Sydney, Australia.

PDS Biotechnology NASDAQ:PDSB

$0.81 -0.04 (-4.36%)

Closing price 09/18/2026 04:00 PM Eastern

Extended Trading

$0.83 +0.02 (+2.55%)

As of 09/18/2026 07:59 PM Eastern

PDS Biotechnology Corporation, a clinical-stage biopharmaceutical company, developing a pipeline of targeted cancer immunotherapies in the United States. The company's lead product candidate is PDS0101 (HPV16), which is in Phase II clinical trial provides a first line treatment for the recurrent/metastatic head and neck cancer, and human papillomavirus associated malignancies. It also develops various product candidates, which are in preclinical trials, including PDS0102, an investigational immunotherapy utilizing tumor-associated and immunologically active T cell receptor gamma alternate reading framed protein (TARP) for treating prostate and breast cancers; and PDS0103 for ovarian, colorectal, lung, and breast cancers. In addition, the company is developing PDS01ADC, a novel investigational Interleukin 12 fused antibody-drug conjugate that enhances the proliferation, potency, and longevity of T cells in the tumor microenvironment; and PDS0104, a novel investigational Tyrosinase-related Protein 2 targeted immunotherapy that stimulates a potent targeted T cell attack against melanoma. Further, the company provides PDS0202, a novel investigational influenza vaccine that generates broad and robust antibody and T cell responses that provide protection against continually evolving strains of seasonal flu and potentially emerging pandemic flu. It has a license and collaboration agreements with National Institutes of Health, Merck Eprova AG, The U.S. Department of Health and Human Services, and MSD International GmbH. The company was founded in 2005 and is based in Princeton, New Jersey.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PDSB, KZIA, CRBU, and ADCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PDSB, KZIA, CRBU, and ADCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PDSB, KZIA, CRBU, and ADCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB, KZIA, CRBU, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

Caribou Biosciences NASDAQ:CRBU

Novogen NASDAQ:KZIA

PDS Biotechnology NASDAQ:PDSB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest PDSB, KZIA, CRBU, and ADCT Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest PDSB, KZIA, CRBU, and ADCT Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

PDSB, KZIA, CRBU, and ADCT Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

PDSB, KZIA, CRBU, and ADCT Company Descriptions

ADC Therapeutics NYSE:ADCT

Caribou Biosciences NASDAQ:CRBU

Novogen NASDAQ:KZIA

PDS Biotechnology NASDAQ:PDSB

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools